Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 1 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 36 % of short-term debt in 2025; threshold 65 %.
-
Shrinking team NBB
FTE fell two years in a row, from 4.6 to 3.7.
Financials
Financial year 2025
PHARMA PETILLON from Etterbeek, company number BE0860445824, closed financial year 2025 with a result of € -11,225 after tax. For that financial year PHARMA PETILLON recorded a gross margin of € 373,326 and equity of € -6,910. Compared with financial year 2024, the result moved from € -17,543 to € -11,225. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 27, 2026.
€ -6,910
▼ € 11,225 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -11,225
▲ 36 % less loss than in 2024
Profit after tax over the fiscal year.
€ 6,382
▼ 82% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -25,510.
People and assets in 2025
3.7
▼ 0.5 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 300,213
▼ 1% vs 2024
€ 81,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 14,499
▼ 55% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 400,755
▼ 18% vs 2024
€ 117,236 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.
€ 242,727
▲ 9% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 46,227
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 383,566 | € 396,612 | € 381,254 | € 373,326 | ▼ 2% |
| Profit after taxes | € 75,015 | € 29,141 | € -17,543 | € -11,225 | ▲ € 6,318 |
| Equity | € 21,717 | € 21,858 | € 4,315 | € -6,910 | ▼ € 11,225 |
| Total debts | € 1,043,816 | € 1,032,194 | € 931,775 | € 830,794 | ▼ 11% |
| Cash | € 34,511 | € 12,280 | € 35,933 | € 6,382 | ▼ 82% |
| Land & buildings | € 562,696 | € 517,609 | € 473,303 | € 430,022 | ▼ 9% |
| Retained profit | € 3,117 | € 3,258 | € -14,285 | € -25,510 | ▼ € 11,225 |
| Dividend | € 74,900 | € 29,000 | € 0 | € 0 | |
| Bank debt | € 569,433 | € 533,173 | € 486,122 | € 400,755 | ▼ 18% |
| Balance sheet total | € 1,065,533 | € 1,054,052 | € 936,090 | € 823,884 | ▼ 12% |
| Employees (FTE) | 3.4 | 4.6 | 4.2 | 3.7 | ▼ 0.5 |
Key figures of PHARMA PETILLON, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to PHARMA PETILLON?
What happened at PHARMA PETILLON in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 11,225. Source: NBB ↗
- TRAP SERVICES BV became a director. NBB
- New establishment in Etterbeek. KBO
- Start of the company according to the CBE. KBO
In short
From € 75,015 profit in 2022 to € 11,225 loss in 2025.
Paid € 6,232 in corporate taxes since 2022.
Best year ever: 2022, with € 75,015 profit.
On average € 100,900 of value added per employee in 2025.
A new publication or filing at PHARMA PETILLON? We notify you, reason included.
Follow PHARMA PETILLONDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind PHARMA PETILLON is TRAP SERVICES BV. TRAP SERVICES BV is also behind APOTHEEK TRAP and PHARMACIE HANKAR.
Directors
According to the 2025 annual accounts
since 2006
Establishments
Establishment units
Physical locations of this company
Vrijwilligerslaan 30
1040 Etterbeek
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0860.445.824
- VAT number
- BE 0860.445.824
- Registered office
- Vrijwilligerslaan 30, 1040 Etterbeek
- Names & denominations
- PHARMA PETILLON
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 11 September 2003
- Peppol
- Active · Active since 21 Nov 2025
- Activities · NACE
Detailhandel in farmaceutische producten
Apothekers